Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to assess the efficacy and safety of vildagliptin 50 mg bid add-on therapy to improve overall glycemic control in patients with T2DM inadequately controlled by insulin, with or without concomitant metformin treatment. It was agreed with PMDA to conduct a postmarketing clinical trial to further collect the efficacy and safety data of vildagliptin especially in Japanese patients when it iwas used on top of insulin.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02002221
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 4
Start date December 2013
Completion date February 2015

See also
  Status Clinical Trial Phase
Recruiting NCT05102149 - Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus Phase 3
Withdrawn NCT03423355 - Dapagliflozin Effect on Erythropoiesis and Physical Fitness Phase 4
Terminated NCT01923389 - Multiple Dose Study Of PF-05231023 In Obese Adult Subjects Phase 1
Completed NCT02218099 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease Phase 1/Phase 2
Completed NCT05607160 - A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Completed NCT05628090 - A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Completed NCT01002807 - Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State Phase 1
Recruiting NCT04943861 - Human Immunodeficiency Virus (HIV) Food Insecurities N/A
Completed NCT02759107 - A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) Phase 1
Completed NCT02643797 - Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings Phase 3
Completed NCT05294458 - A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects Phase 1
Recruiting NCT06327815 - Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM Phase 4
Completed NCT02219646 - Diabetes & Vardenafil Phase 2
Recruiting NCT05761301 - A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM Phase 1/Phase 2
Completed NCT04504396 - Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy Phase 3
Completed NCT01991093 - Multiple Electrode Aggregometry & Clopidogrel Resistance
Completed NCT01871558 - Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin Phase 3
Completed NCT01407003 - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1/Phase 2
Completed NCT01127308 - A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038) Phase 1